Positive Developments for MAC Lung Disease Drug as U.S. Bio CEO and Executives Sell Millions in Stock

Insmed Inc. (INSM) announced on March 23 that its Phase 3b ENCORE trial of ARIKAYCE for Mycobacterium avium complex (MAC) lung disease delivered positive results, and the company plans to submit additional New Drug Application (NDA) supplement materials to the U.S. Food and Drug Administration (FDA) and file for an expanded indication with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in the second half of this year. Earlier, on March 5, CEO William Lewis exercised stock options and sold approximately 10,000 shares, raising about $1.56 million (roughly KRW 2 billion). On March 30, the Chief Legal Officer sold about 19,000 shares after exercising options, realizing gains of around $2.97 million (about KRW 4 billion). Filings show Lewis still directly holds some 300,000 shares—valued at about $44 million (KRW 60 billion) based on recent closing prices.

Following the ENCORE results, Morgan Stanley upgraded Insmed to “Overweight” and raised its price target to $212, while Barclays lifted its target to $237. Other major brokerages have similarly raised their outlooks, and Insmed’s stock jumped roughly 6% immediately after analysts’ upgrades at the end of March, drawing increased investor interest in the U.S. biotech sector. ()

Headquartered in Bridgewater, New Jersey, Insmed is a biopharmaceutical company dedicated to developing treatments for rare and serious pulmonary diseases, including non-tuberculous mycobacterial lung infections. The company is commercializing ARIKAYCE for MAC lung disease and is advancing a respiratory-focused pipeline that includes the oral anti-inflammatory brensocatib and treprostinil palmitil inhalation powder for pulmonary arterial hypertension. ()